Author + information
- Received February 13, 2019
- Revision received August 2, 2019
- Accepted September 3, 2019
- Published online July 6, 2020.
- Roshin C. Mathew, MDa,
- Jamieson M. Bourque, MDa,b,
- Michael Salerno, MD, PhD, MSa,b,c and
- Christopher M. Kramer, MDa,b,∗ ()
- aDepartment of Medicine (Cardiology), University of Virginia Health System, Charlottesville, Virginia
- bDepartment of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia
- cDepartment of Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia
- ↵∗Address for correspondence:
Dr. Christopher M. Kramer, University of Virginia Health System, Division of Cardiovascular Medicine, 1215 Lee Street, Box 800158, Charlottesville, Virginia 22908.
• The authors discuss the nuances of MBF and MPR quantification in imaging modalities.
• Each modality, with advantages and disadvantages, has played a role in detecting MVD.
• PET-derived MBF offers the most prognostic data to date on the impact of MVD.
• Research on MBF quantification by CMR is growing as CMR becomes more accessible.
The understanding of microvascular dysfunction without evidence of epicardial coronary artery disease pales in comparison with that of obstructive epicardial coronary artery disease. A primary limitation in the past had been the lack of development of noninvasive methods of detecting and quantifying microvascular dysfunction. This limitation has particularly affected the ability to study the pathophysiology, morbidity, and treatment of this disease. More recently, almost all of the noninvasive cardiac imaging modalities have been used to quantify blood flow and advance understanding of microvascular dysfunction.
- cardiac magnetic resonance
- computed tomography
- microvascular dysfunction
- positron emission tomography
- quantitative perfusion
This paper was supported by NHLBI grant T32 EB003841. Dr. Bourque has received support from NIH grant 5K23HL119620-02. Dr. Salerno has received research support from AstraZeneca and Siemens Healthineers; and has received support from NIH grant 5R01HL131919-02. Dr. Kramer has received support from NHLBI grants R01 HL075792 and U01HL117006-01A1. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Imaging author instructions page.
- Received February 13, 2019.
- Revision received August 2, 2019.
- Accepted September 3, 2019.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.